MG
RXRX icon

Mather Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Mather Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Buy
+2,280
New +$8.81K ﹤0.01% 1526
2025
Q4 		– Sell
-1,030
Closed -$5.03K – 1454
2025
Q3 		$5.03K Buy
+1,030
New +$5.41K ﹤0.01% 1393

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mather Group's RXRX Position: Q1 2026 in Review

Mather Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 2,280 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1526 among its holdings. This is a return to the name: Mather Group previously reported a position in RXRX as recently as Q3 2025.

Mather Group first reported a position in RXRX in Q3 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Mather Group held 2,280 shares of Recursion Pharmaceuticals worth $7K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Mather Group position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1526 holding.
  • Mather Group first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.